

# Germany Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032

Market Report | 2023-05-01 | 83 pages | Allied Market Research

#### **AVAILABLE LICENSES:**

- Cloud Access License \$2119.50
- Business User License \$3213.00
- Enterprise License \$4995.00

#### **Report description:**

Radiopharmaceuticals are drug-producing compounds of contaminated materials that are utilized in medical imaging and also cancer cells treatments. They are carried out intravenously to people for detecting and treating malignant as well as benign growths, cardiovascular diseases, as well as neurological illness. Germany is just one of the leading markets for radiopharmaceuticals in Europe. The nation is taking innovative steps to establish brand-new items, innovations, and solutions to satisfy its radiopharmaceuticals require. The market place for radiopharmaceuticals in Germany is approximated to be valued at around EUR 349 million in 2020, and is approximated to reach around EUR 417 million in 2025, revealing a CAGR of 4.1% during 2020-2025.

In recent years, the demand for radiopharmaceuticals in Germany has actually been gradually increasing due to the increasing frequency of cancer cells, including lung cancer cells. The raising occurrence of cardiovascular diseases, such as cardiac arrest and also stroke, as well as the growing demand for efficient diagnostics and also proper treatment for them, are some of the significant motive power behind the growth of the radiopharmaceuticals market in Germany. Additionally, the government's assistance for performing scientific trials and also its investments in r & d (R&D) activities to create novel drugs as well as techniques that will improve the effectiveness of radiopharmaceuticals is also supplying incentive to the growth of the market. On the other hand, the absence of experienced personnel for manufacturing and also operating complicated radiopharmaceutical systems, the limited accessibility of radiopharmaceuticals, the high cost of radiopharmaceuticals, as well as the rigorous policies troubled the manufacturing and distribution of radiopharmaceuticals may prevent the growth of the market.

Radiopharmaceuticals have great possible to open up brand-new avenues for clinical diagnosis and also therapy, as they offer specific and also reliable techniques for tracking as well as treating numerous conditions. Innovations in imaging technology as

well as the advancement of novel radiolabeled medications are several of the crucial possibilities in the German market. On top of that, with the surge in the number of professional trials to establish much more reliable radiopharmaceuticals as well as capitalize on the expanding demand for customized medicines, the radiopharmaceuticals market in Germany is anticipated to witness a significant surge in development opportunities.

Moreover, the growth of ingenious drug-targeted radiopharmaceuticals will certainly be useful for the market as it will certainly allow a lot more effective individual administration and the delivery of personalized medicines. These trends are anticipated to bring fresh chances for players in the radiopharmaceuticals market in Germany.

Radiopharmaceuticals go through rigorous guidelines. In Germany, these laws are set by different organizations, consisting of the Federal Institute for Drugs as well as Medical Gadget (BfArM); the Federal Office for Radiation Protection (BfS); and also the Technical Standard on Radiopharmacy Therapy, which sets criteria for the production of radiopharmaceuticals as well as their control in Germany. These laws are implemented to make certain a secure and effective production and also professional use of radiopharmaceuticals, hence keeping the standards of high quality as well as continuing to promote security in the medical field. The Germany radiopharmaceuticals market is fractional by radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), by application (Cancer, Cardiology, Others), by kind (Diagnostics, Restorative), as well as by end individual (Healthcare facilities and also clinics, Medical Imaging Centers, Others). Among the sectors, Technetium 99m held the biggest share in the marketplace in 2019, adhered to by Fluorine 18 and Iodine. Technetium 99m is generally utilized for medical imaging applications such as positron discharge tomography and single-photon discharge computed tomography scans, while Fluorine 18 and Iodine are utilized primarily in oncology for the medical diagnosis as well as treatment of cancer cells.

The Germany radiopharmaceuticals market is a fairly combined market, with a couple of huge gamers running in it. The affordable atmosphere on the market is influenced primarily by the bargaining power of distributors as well as purchasers, the danger of new participants, the threat of replacements, and also the intensity of rivalry amongst existing players. Vendors have restricted bargaining power out there, as there are a couple of makers of radiopharmaceuticals and also the costs are very managed. Purchasers[]on the other hand, have considerable negotiating power due to the visibility of several different choices available for clinical imaging as well as therapy. The danger of brand-new entrants is reduced due to the existence of strict governing framework on the market. The danger of replacements is modest, as radiopharmaceuticals are irreplaceable Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in Germany radiopharmaceuticals market.

Assess and rank the top factors that are expected to affect the growth of Germany radiopharmaceuticals market.

Top player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the Germany radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

- Quarterly Update and\* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.

- 16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

- 15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response\*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
- Key Market Segments
- Ву Туре
- Diagnostic
- Therapeutic
- By End User
- Hospitals and clinics
- Medical Imaging centers
- Others
- By Radioisotope
- Fluorine 18
- lodine l
- Gallium 68
- Others
- Technetium 99m
- By Application
- Cancer
- Cardiology
- Others
- Key Market Players
- Advanced Accelerator Applications
- Progenics Pharmaceuticals
- Curium
- BERLIN-CHEMIE AG
- EOS imaging
- Fujirebio Europe
- IDC Basel
- IBA Molecular
- Mallinckrodt Pharmaceuticals
- Nuclear Pharmacy Services GmbH

### **Table of Contents:**

- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology

1.4.1. Primary Research 1.4.2. Secondary Research 1.4.3. Analyst Tools and Models CHAPTER 2: EXECUTIVE SUMMARY 2.1. CXO Perspective CHAPTER 3: MARKET OVERVIEW 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top Impacting Factors 3.2.2. Top Investment Pockets 3.3. Porter's Five Forces Analysis 3.4. Market Dynamics 3.4.1. Drivers 3.4.2. Restraints 3.4.3. Opportunities 3.5. COVID-19 Impact Analysis on the market CHAPTER 4: GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE 4.1. Overview 4.1.1. Market Size and Forecast, By Radioisotope 4.2. Technetium 99m 4.3. Fluorine 18 4.4. lodine l 4.5. Gallium 68 4.6. Others CHAPTER 5: GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION 5.1. Overview 5.1.1. Market Size and Forecast, By Application 5.2. Cancer 5.3. Cardiology 5.4. Others CHAPTER 6: GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE 6.1. Overview 6.1.1. Market Size and Forecast, By Type 6.2. Diagnostic 6.3. Therapeutic CHAPTER 7: GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER 7.1. Overview 7.1.1. Market Size and Forecast, By End User 7.2. Hospitals and clinics 7.3. Medical Imaging centers 7.4. Others **CHAPTER 8: COMPETITIVE LANDSCAPE** 8.1. Introduction 8.2. Top winning strategies 8.3. Product Mapping of Top 10 Player 8.4. Competitive Dashboard

8.5. Competitive Heatmap

- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Company 1
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Company 2
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Company 3
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Company 4
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Company 5
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Company 6
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments

- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Company 7
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Company 8
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Company 9
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Company 10
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

Scotts International. EU Vat number: PL 6772247784 tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



# Germany Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032

Market Report | 2023-05-01 | 83 pages | Allied Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

### **ORDER FORM:**

Select license	License		Price
	Cloud Access License		\$2119.50
	Business User License		\$3213.00
	Enterprise License		\$4995.00
		VAT	
		Total	

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP	number*
Address*	City*	
Zip Code*	Country*	

Date

2025-05-07

Signature